B-lymphocyte antigen CD20, B-cell receptor CD22, Tetraspanin-37, and B-cell activating factor receptor (CD268) (CD20/CD22/CD37/BAFF-R)

The target set comprising CD20, CD22, CD37, and CD268 (BAFF-R) represents a cluster of B-cell lineage-specific surface antigens that are highly expressed in various B-cell malignancies. These proteins play critical roles in B-cell biology: CD20 is involved in calcium signaling and B-cell receptor (BCR) modulation; CD22 acts as an inhibitory co-receptor for the BCR; CD37 is a tetraspanin that organizes membrane microdomains; and BAFF-R is essential for B-cell survival and maturation (1, 9, 11, 17). In the context of oncology, these antigens are targeted simultaneously to overcome the challenge of antigen escape, where tumor cells downregulate a single target to evade immunotherapy (4, 13, 14). A notable therapeutic approach targeting this specific combination is Enterome's EO2463, an OncoMimics immunotherapy that uses microbial-derived peptides to activate CD8+ T cells against these four markers (1, 7, 8). This multi-antigen strategy is primarily being investigated for indolent non-Hodgkin lymphomas, such as follicular and marginal zone lymphomas, aiming to provide broad and durable anti-tumor activity while minimizing resistance (4, 5).

Other names

MS4A1SIGLEC2TSPAN26TNFRSF13CB-lymphocyte antigen CD20B-cell receptor CD22Tetraspanin-37B-cell activating factor receptorBAFF-RBL-CAMB1Bp35GP52-40BROMAR

T-cell activation via molecular mimicry (EO2463), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and chimeric antigen receptor (CAR) T-cell mediated lysis.